Q3 2019 Emerging Medical Technologies Spotlight

Virtual Events Starts: Friday, September 27

Colospan (fka Cologuard)

Colorectal surgery technology aiming to prevent the profound clinical and economic pains associated with colorectal anastomotic leaks and diverting stomas
Key Executive
Colospan (fka Cologuard)

Boaz Assaf

Address:

City: Kfar Saba

Country: Israel

Year Established: 2011

Company Details
Company Status

Financing Status: Not currently raising money

Regulatory/Development Status: CE Marked, Pilot clinical trial completed ready to launch FDA pivotal trial

Additional details: Colospan's device is meant to prevent or delay the for need colostomy - the surgical creation of an external bypass for the intestine or colon following the removal of a diseased part. It can be temporary, giving the gut time to heal before the healthy parts of the intestines are reattached, or permanent. Colospan's device creates an internal bypass and can be removed non-surgically after 10 days.

In October 2017, the company announced that it had raised $8M in a funding round, led by healthcare-focused venture capital fund TriVentures and an undisclosed international medical device company. Colospan intends to use the funding for a clinical trial towards approval from the U.S. FDA, and also to market the device in Europe based on its CE Mark approval, received in 2014.

Deals
11/15/17

Type: Financing

Technology: Colorectal surgery technology aiming to prevent the profound clinical and economic pains associated with colorectal anastomotic leaks and diverting stomas

Amount: $8,000,000

Investors/Acquirer: Led by healthcare-focused venture capital fund TriVentures and an undisclosed international medical device company.